Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» IPE receives FDA approval for Phase 2 clinical trials for BCT303 for hypothyroidism
IPE receives FDA approval for Phase 2 clinical trials for BCT303 for hypothyroidism
IPE receives FDA approval for Phase 2 clinical trials for BCT303 for hypothyroidism
Submitted by
admin
on January 30, 2013 - 1:30pm
Source:
CP Wire
News Tags:
IPE
FDA
BCT303
BCT404
hypothyroidism
Headline:
IPE receives FDA approval for Phase 2 clinical trials for BCT303 for hypothyroidism
Do Not Allow Advertisers to Use My Personal information
